Replies to post #97045 on Innovation Pharmaceuticals Inc (IPIX)

[scottsmith]

Here is the one that matters most:

http://eccmid.meetingexpert.net/ECCMID_546/faculty_4548639/faculty.aspx

[daydreaming2]

Somebody's buying and apparently you want to buy also,just not at this price (or you wouldn't be here).

Pretty transparent!

GLTA

[TOB]

What nonsense.

Leo did announce with great emphasis "what this small company is doing" (three presentations) which have no trace on ECCMID website scheduled for this month. -drgastro_va

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

[TOB]

More nonsense.

Leo did announce the Ulcerative Procitits trial while he has his hands full and nothing substantial to show ....he has nothing to sell to anyone and no one is really buying the stock. -drgastro_va

This shows Cellceutix is moving forward with multiple indications. This is based upon completed research from the PolyMedix acquisition which has been confirmed by further research at Cellceutix. "Hands full" is nonsense, they have sufficient research staff and have made key additions.

Cellceutix added James Alexander, MD, MPH, FACP as Chief Operating Officer, and formerly of PolyMedix, Daniel Jorgensen, MD, MPH, MBA, FAAP as Chief Medical Officer. This in addition to a full research and support staff. They hardly have their "hands full" as proven by how productive they are. They took Brilacidin from acquisition to a P2b clinical trial successful completion in just over a year. A remarkable accomplishment.

"Nothing substantial to show" is more nonsense, there is the recently completed Phase 2b Clinical Trial for Brilacidin with positive top-line results. A successful clinical trial. Further detail to debut this month at a leading industry convention, ECCMID 2015. A successful clinical trial is very substantial for a clinical stage biotech.

The Prurisol trial completed successfully.

The Kevetrin trial is continuing successfully, an almost certain Phase 1 primary outcome measure success at this point, with a latter stage trial already approved and standing by to begin.

A Brilacidin-OM trial is approved, also based upon completed PolyMedix research.

Here is a link to Cellceutix trials: https://www.clinicaltrials.gov/ct2/results?term=cellceutix&Search=Search

Cellceutix just closed a $30 million financing deal, it's third with Aspire Capital. This is substantial and gives Cellceutix funds necessary to move forward on all planned investigational drugs, both in clinical trials and in pre-clinical research.

Cellceutix has applied for up-listing with the NASDAQ.

What Cellceutix does not have is even one failed clinical trial, everything is coming up roses. There is a tremendous amount of substance shown by Cellceutix.

[WILD_4_IPIX]

I'm trying to buy 3000 more shares right now and only have 400 even though I raised my bid price !

GO CTIX !